Knowledge Management System of Hefei Institute of Physical Science,CAS
Trastuzumab in combination with chemotherapy for HER2-positive metastatic gastric cancer patients underwent conversion therapy | |
Zhang, Yanqiang1; Xu, Xiaoqing2; Hu, Can2; Du, Yian1; Ding, Guangyu1; Chen, Jiahui1; Zhu, Xiu3; Xu, Zhiyuan1,6; Wei, Qing4,5 | |
2022-07-01 | |
发表期刊 | TRANSLATIONAL CANCER RESEARCH |
ISSN | 2218-676X |
通讯作者 | Xu, Zhiyuan(getfar@foxmail.com) ; Wei, Qing(weiqingmd@163.com) |
摘要 | Background: Conversion surgery is a treatment that aims for R0 resection of primary advanced gastric cancers (GCs) that have responded well to systemic chemotherapy. We investigated the role of conversion therapy in initially unresectable metastatic cancer with positive HER2 status that responded to chemotherapy plus trastuzumab. Methods: A total of 32 metastatic GC patients who underwent systemic chemotherapy plus trastuzumab sequenced by conversion surgery at Zhejiang Cancer Hospital between 2015 and 2020 were retrospectively reviewed. Results: The observed overall survival (OS) and progression-free survival (PFS) for all the patients were 30.2 and 25.1 months, respectively. The 1-year survival rate was 81.25%, and the 1-year PFS rate was 78.13%. Univariate and multivariate analyses demonstrated that liver metastasis (P=0.021), peritoneal metastasis (P=0.047), para-aortic lymph node metastasis (16a1/b2) (P=0.048), macroscopic type 4 (P=0.027), number of noncurative factors (P=0.011), Yoshida et al. category (P=0.021), and inductive chemotherapy cycles (P=0.025) were independent prognostic factors for OS. Conclusions: HER2-positive patients with potentially resectable disease had a remarkably good prognosis after conversion gastrectomy following trastuzumab treatment. Adequate selection of metastatic GC patients for conversion surgery is recommended. |
关键词 | Gastric cancer HER2-positive conversion therapy |
DOI | 10.21037/tcr-21-2886 |
关键词[WOS] | NIVOLUMAB PLUS CHEMOTHERAPY ; GASTROESOPHAGEAL JUNCTION ; OPEN-LABEL ; PHASE-II ; OXALIPLATIN ; SURGERY |
收录类别 | SCI |
语种 | 英语 |
资助项目 | Medical Health Science and Technology Project of Zhejiang Provincial Health Commission[2022KY684] |
项目资助者 | Medical Health Science and Technology Project of Zhejiang Provincial Health Commission |
WOS研究方向 | Oncology |
WOS类目 | Oncology |
WOS记录号 | WOS:000811139700001 |
出版者 | AME PUBLISHING COMPANY |
引用统计 | |
文献类型 | 期刊论文 |
条目标识符 | http://ir.hfcas.ac.cn:8080/handle/334002/130386 |
专题 | 中国科学院合肥物质科学研究院 |
通讯作者 | Xu, Zhiyuan; Wei, Qing |
作者单位 | 1.Chinese Acad Sci, Univ Chinese Acad Sci Zhejiang Canc Hosp, Inst Basic Med & Canc IBMC, Canc Hosp, Hangzhou, Peoples R China 2.Second Clin Med Coll Zhejiang Chinese Med Univ, Hangzhou, Peoples R China 3.Chinese Acad Sci, Univ Chinese Acad Sci Zhejiang Canc Hosp, Inst Basic Med & Canc IBMC, Canc Hosp, Hangzhou, Peoples R China 4.Chinese Acad Sci, Univ Chinese Acad Sci Zhejiang Canc Hosp, Inst Basic Med & Canc IBMC, Canc Hosp, Hangzhou, Peoples R China 5.Univ Chinese Acad Sci, Chinese Acad Sci, Inst Basic Med & Canc IBMC, Canc Hosp, 1 East Banshan Rd, Hangzhou 310000, Peoples R China 6.Univ Chinese Acad Sci, Chinese Acad Sci, Inst Basic Med & Canc IBMC, Canc Hosp, 1 East Banshan Rd, Hangzhou 310000, Peoples R China |
推荐引用方式 GB/T 7714 | Zhang, Yanqiang,Xu, Xiaoqing,Hu, Can,et al. Trastuzumab in combination with chemotherapy for HER2-positive metastatic gastric cancer patients underwent conversion therapy[J]. TRANSLATIONAL CANCER RESEARCH,2022,11. |
APA | Zhang, Yanqiang.,Xu, Xiaoqing.,Hu, Can.,Du, Yian.,Ding, Guangyu.,...&Wei, Qing.(2022).Trastuzumab in combination with chemotherapy for HER2-positive metastatic gastric cancer patients underwent conversion therapy.TRANSLATIONAL CANCER RESEARCH,11. |
MLA | Zhang, Yanqiang,et al."Trastuzumab in combination with chemotherapy for HER2-positive metastatic gastric cancer patients underwent conversion therapy".TRANSLATIONAL CANCER RESEARCH 11(2022). |
条目包含的文件 | 条目无相关文件。 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论